Adhesion to high-performance polymers applied in dentistry: A systematic review

OBJECTIVE

The aim of this systemic review, conducted in accordance with the PRISMA statement, was to investigate the impact of surface pretreatments on the bonding strength of high performance polymers (HPPs).

METHODS

Eight databases were searched through March 2019. Risk of bias was assessed and random effects meta-analyses were applied to analyze mean differences in shear bond strength (SBS) and tensile bond strength (TBS), considering surface pretreatments and bonding agents after 24h and thermocycling.

RESULTS

A total of 235 relevant titles and abstracts were found, yielding 11 final selections. Low risk of bias was observed in most studies. For polyetheretherketone (PEEK) specimens, random-effect models showed that, compared to non-treated controls, pretreatments associated with Visio.link® (Bredent, Senden, GE) increased TBS by 26.72MPa (95% confidence interval (CI), 19.69-33.76; p<0.00001) and increased SBS by 4.86MPa (95% CI, 2.61-7.10; p<0.00001). Air abrasion improved SBS by 4.90MPa (95% CI, 3.90-5.90; p<0.00001) (50μm alumina) and 4.51MPa (95% CI, 1.85-7.18; p=0.0009) (silica-coated CoJet). In comparison to non-treated controls, Visio.link® and Signum PEEK Bond® (Heraeus Kulzer, Hanau, GE) increased SBS by 33.76MPa (95% CI, 18.72-48.81; p<0.00001) and 33.28MPa (95% CI, 17.48-49.07; p<0.00001), respectively. No differences were found between Visio.link® and Signum PEEK Bond® or Monobond Plus/Heliobond® (Ivoclar Vivadent, Schaan, LH) (p>0.05). Similar results were observed for polyetherketoneketone (PEKK) specimens.

SIGNIFICANCE

This review shows improved HPP bonding following the application of various surface pretreatments, including air abrasion and bonding agents.

Diagnostic accuracy of serum biomarkers for head and neck cancer: A systematic review and meta-analysis

Serum biomarkers could be helpful to characterize head and neck squamous cell carcinoma (HNSCC). Thus, the purpose of this systematic review and meta-analysis was to determine the diagnostic capability of serum biomarkers in the assessment of HNSCC patients. Studies were gathered by searching LILACS, PubMed, Science Direct, Scopus and Web of Science up to April 10th, 2015. Studies that focused on serum biomarkers in the diagnosis of HNSCC compared with controls were considered. Sixty-five studies were identified, and the sample size included 9098 subjects. Combined biomarkers demonstrated improved accuracy than those tested individually. Therefore, 12.8% of single and 34.3% of combined indicated that serum biomarkers discriminate patients with HNSCC from controls. The combined biomarkers with better diagnostic capability included Epidermal growth factor receptor (EGFR)+Cyclin D1 and squamous cell cancer-associated antigen (SCCA)+EGFR+Cyclin D1. Beta2-microglobin may also be a promising single biomarker for future studies. Serum biomarkers can be potentially useful in the diagnosis of HNSCC. However, further research is required to validate these biomarkers.